mitogen-activated protein kinase 8 interacting protein 3Genealiases: JIP-3 · JIP3 · JSAP1 · NEDBA · SYD2 · syd
Q-omics provides the consensus-scored MAPK8IP3 profile across patient tissues and cancer cell-line models. MAPK8IP3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAPK8IP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MAPK8IP3 RNA expression shows 19,674 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where MAPK8IP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK8IP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK8IP3 survival associations across molecular data types. MAPK8IP3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK8IP3 RNA expression–survival associations across cancer types. High MAPK8IP3 expression shows unfavorable associations in KIRC, UVM and MESO, but favorable associations in BLCA, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAPK8IP3 RNA expression.
This table summarizes MAPK8IP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAPK8IP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK8IP3 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, KIRP and CHOL. The KIRC box plot shows higher MAPK8IP3 RNA expression in tumor versus normal tissue (log2 FC = +1.138, t-test p < 0.001).
This table shows molecular features associated with MAPK8IP3 in patient tissues and cancer cell lines. In patient samples, MAPK8IP3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK8IP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
